Study to evaluate the efficacy and safety of oral rilzabrutinib in adults with immune thrombocytopenia (ITP) who failed first-line treatment

Trial Identifier: LPS18573
Sponsor: Sanofi
Start Date: October 2025
Primary Completion Date: November 2027
Study Completion Date: December 2028
Condition: Heart, Blood & Circulatory - Other

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

No documents have been posted yet.

Trial Locations

Country Location
Austria Vienna, Austria, 1140
France Creteil, France, 94000
France Dijon, France, 21079
France Pessac, France, 33604
France Toulouse, France, 31059
Hungary Kaposvar, Hungary, 7400
Italy Naples, Italy, 80131
Italy Torino, Italy, 10126
Italy Vicenza, Italy, 36100
Poland Gdansk, Poland, 80-219
Poland Skorzewo, Poland, 60-185
Poland Slupsk, Poland, 76-200
Spain Barcelona, Spain, 8003
Spain Burgos, Spain, 9006
Spain Madrid, Spain, 28046
Spain Madrid, Spain, 28007
Spain Murcia, Spain, 30008
Spain Sevilla, Spain, 41013
United States, Louisiana New Orleans, Louisiana, United States, 70112
United States, Michigan Ann Arbor, Michigan, United States, 48109
United States, Minnesota Rochester, Minnesota, United States, 55905
United States, New York Albany, New York, United States, 12208
United States, New York Bronx, New York, United States, 10467
United States, Utah Ogden, Utah, United States, 84405